Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor

Abstract

WEB 2086, a thieno-triazolodiazepine, is a potent and specific antagonist of platelet activating factor (PAF) in vitro and in vivo. This compound inhibits PAF-induced human platelet and neutrophil aggregation in vitro (IC50 = 0.17 and 0.36 microM, respectively) but has little or no effect on the action of other platelet aggregating agents. In comparison with kadsurenone, ketotifen or thiazinamium chloride, WEB 2086 was 26 to 200 times more potent in the PAF-induced platelet aggregation. In anesthetized guinea pigs, pretreatment with 0.1 to 2.0 mg/kg p.o. or 0.01 to 0.5 mg/kg i.v. of WEB 2086 inhibits dose-dependently the accumulation and aggregation of 111Indium labeled platelets, bronchoconstriction, systemic hypotension and also the lethal effect due to an i.v. PAF infusion [30 ng/(kg X min)] or intratracheal instillation of PAF (300 micrograms/kg). Under the same experimental conditions in guinea pigs, WEB 2086 given by inhalation achieved a similar anti-PAF activity. In anesthetized rats, the hypotension induced by an i.v. PAF infusion was also reversed (ED50 = 0.052 mg/kg i.v.). The increase in cutaneous vascular permeability due to intradermal PAF (25 ng/site) was inhibited dose-dependently by WEB 2086 (0.025-2 micrograms/site) in rats. Because of its structural relationship to triazolodiazepines, WEB 2086 was examined for anticonvulsant and sedative action. Up to doses of 300 and 800 mg/kg p.o., respectively, no effects were found. In conclusion, WEB 2086 is a potent and specific PAF antagonist with triazolodiazepine structure but without sedative activity.